Core Laboratories Inc. (NYSE:CLB – Free Report) – Equities research analysts at Zacks Research boosted their Q1 2028 EPS estimates for Core Laboratories in a note issued to investors on Wednesday, June 17th. Zacks Research analyst Team now expects that the oil and gas company will post earnings of $0.24 per share for the quarter, up from their prior estimate of $0.23. The consensus estimate for Core Laboratories’ current full-year earnings is $0.56 per share.
A number of other research firms also recently commented on CLB. Wall Street Zen downgraded Core Laboratories from a “hold” rating to a “sell” rating in a report on Monday, May 25th. Weiss Ratings cut Core Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Core Laboratories currently has an average rating of “Hold” and an average target price of $12.00.
Core Laboratories Stock Up 2.2%
Shares of CLB opened at $11.68 on Friday. Core Laboratories has a fifty-two week low of $9.72 and a fifty-two week high of $20.36. The company’s fifty day moving average is $14.53 and its two-hundred day moving average is $16.42. The firm has a market cap of $538.49 million, a PE ratio of 17.97, a price-to-earnings-growth ratio of 2.21 and a beta of 0.98. The company has a quick ratio of 1.50, a current ratio of 2.05 and a debt-to-equity ratio of 0.42.
Core Laboratories (NYSE:CLB – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The oil and gas company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $121.80 million during the quarter, compared to analyst estimates of $122.99 million. Core Laboratories had a net margin of 5.94% and a return on equity of 11.52%. Core Laboratories’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.14 earnings per share. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS.
Institutional Investors Weigh In On Core Laboratories
Institutional investors have recently bought and sold shares of the business. CWA Asset Management Group LLC acquired a new stake in shares of Core Laboratories in the fourth quarter worth $9,978,000. Goldman Sachs Group Inc. lifted its holdings in shares of Core Laboratories by 185.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock valued at $13,549,000 after acquiring an additional 548,657 shares in the last quarter. Disciplined Growth Investors Inc. MN lifted its holdings in shares of Core Laboratories by 9.7% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock valued at $73,787,000 after acquiring an additional 528,976 shares in the last quarter. MAC Alpha Capital Management LP purchased a new stake in Core Laboratories during the 4th quarter worth $5,016,000. Finally, Heartland Advisors Inc. purchased a new stake in Core Laboratories during the 1st quarter worth $2,518,000. 97.81% of the stock is currently owned by hedge funds and other institutional investors.
Core Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Monday, May 11th were issued a $0.01 dividend. The ex-dividend date was Monday, May 11th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is presently 6.15%.
About Core Laboratories
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company’s portfolio spans two primary service lines: reservoir description and production enhancement.
Featured Stories
- Five stocks we like better than Core Laboratories
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
